Repligen (RGEN)
(Delayed Data from NSDQ)
$138.82 USD
+4.33 (3.22%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $139.50 +0.68 (0.49%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.82 USD
+4.33 (3.22%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $139.50 +0.68 (0.49%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now
by Zacks Equity Research
Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.
J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab
by Zacks Equity Research
J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
by Zacks Equity Research
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day
Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Maravai LifeSciences Holdings, Inc. (MRVI) and Repligen (RGEN) have performed compared to their sector so far this year.
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod
by Zacks Equity Research
ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.
Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag
by Zacks Equity Research
Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.
AstraZeneca's (AZN) Ultomiris sBLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.
Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.
Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline
by Zacks Equity Research
Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.
Repligen (RGEN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.
bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.
Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.
Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline
by Zacks Equity Research
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOG
Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Repligen's (RGEN) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
Repligen (RGEN) beats earnings and sales estimates in the third quarter of 2021.